Vasodilator Therapy in Heart Failure

Pathophysiological Rationale

• Heart failure induces excessive compensatory mechanisms including arteriolar and venous vasoconstriction mediated by catecholamines.
• Arteriolar constriction increases systemic vascular resistance (SVR), increasing cardiac work and afterload.
• Venoconstriction decreases venous capacitance, increasing venous return and elevating ventricular filling pressures (preload).
• Vasodilators counteract inappropriate vasoconstriction, decreasing cardiac work.
• Reductions in SVR and venous tone improve tissue oxygenation, reduce fatigue, and provide better work capacity.

Clinical Indications

• Acute mitral or aortic regurgitation.
• Ventricular dysfunction secondary to myocarditis.
• Anomalous left coronary artery from pulmonary artery (ALCAPA).
• Early postoperative cardiac surgery period.
• Left-to-right shunts (e.g., large VSDs); afterload reduction selectively lowers systemic resistance over pulmonary resistance, decreasing Qp:Qs ratio.
• “Warm-Wet” hemodynamic profile; indicates adequate perfusion with significant congestion.
• “Cold-Wet” hemodynamic profile (cardiogenic shock with high SVR); vasodilators combined with inotropes (or utilizing inodilators) improve perfusion.

Classes of Vasodilators

Oral Vasodilators (Chronic Therapy)

ACE Inhibitors (ACEi)

• First-line oral vasodilators for pediatric heart failure.
• Suppress renin-angiotensin-aldosterone system (RAAS), reducing vasoconstriction, salt retention, and water retention.
• Prevent arrhythmias and adverse myocardial effects by suppressing catecholamine release.
• Exert beneficial effects on cardiac remodeling; decrease myocardial fibrosis formation.

Angiotensin Receptor Blockers (ARBs)

• Utilized primarily when persistent cough necessitates discontinuation of ACE inhibitors.
• Block angiotensin II receptors, achieving similar afterload reduction without bradykinin accumulation.

Angiotensin Receptor-Neprilysin Inhibitors (ARNi)

• Sacubitril/Valsartan combination therapy.
• Inhibits neprilysin (neutral endopeptidase), preventing degradation of circulating natriuretic peptides (BNP), bradykinin, and adrenomedullin.
• Concomitant ARB (valsartan) prevents paradoxical RAAS potentiation.
• Approved for pediatric patients >1 year of age with systemic left ventricular systolic dysfunction.

Intravenous Vasodilators (Acute Therapy)

Direct Vasodilators

• Sodium Nitroprusside: Direct action on venous and arteriolar smooth muscle; acts on both systems. Extreme short half-life allows precise titration for afterload and preload reduction.
• Nitrates (Nitroglycerin): Preferential venodilators. Increase cGMP causing smooth muscle relaxation. Reduce preload greater than afterload.

Inodilators

• Milrinone: Myocardial selective cAMP phosphodiesterase type-3 inhibitor. Increases intracellular cAMP, resulting in vasodilation (lowers SVR/PVR), inotropy, and lusitropy. Preferred first-line vasoactive medication with adequate blood pressure.
• Levosimendan: Calcium sensitizer; opens ATP-sensitive potassium channels without altering intracellular calcium levels. Potent inodilator without increasing arrhythmia risk compared to milrinone.

Pharmacologic Dosing Profiles

Medication	Class	Pediatric Dosing
Captopril	ACEi	0.1–0.5 mg/kg/dose PO q6–24 h (Max: 6 mg/kg/day).
Enalapril	ACEi	0.05–0.1 mg/kg/day PO (Max: 0.5 mg/kg/day).
Lisinopril	ACEi	0.07 mg/kg/dose PO daily (Max: 0.6 mg/kg/day or 40 mg/day).
Losartan	ARB	0.7 mg/kg/day PO (Max: 1.4 mg/kg/day or 100 mg/day).
Valsartan/Sacubitril	ARNi	Weight-based titration (e.g., <40 kg: 1.6 to 3.1 mg/kg BID).
Sodium Nitroprusside	Direct Vasodilator	0.3–0.5 mcg/kg/min IV continuous (Max: 10 mcg/kg/min).
Nitroglycerin	Nitrate	0.25–0.5 mcg/kg/min IV continuous (Usual: 1–5 mcg/kg/min).
Milrinone	Inodilator	0.25–1 mcg/kg/min IV continuous infusion.
Levosimendan	Inodilator	12 mcg/kg loading over 1 h; maintenance 0.1–0.2 mcg/kg/min.

Adverse Effects & Monitoring

RAAS Inhibitors (ACEi / ARB / ARNi)

• First-Dose Hypotension: Initiate at one-quarter calculated dose to prevent acute decompensation.
• Renal Toxicity: Avoid in neonates due to risk of acute kidney injury. Withhold in settings of severe dehydration. Monitor creatinine and electrolytes every 1–2 weeks for initial 4–6 weeks.
• Hyperkalemia: Risk increased when co-administered with spironolactone or potassium supplements; requires regular serum monitoring.

Sodium Nitroprusside

• Cyanide/Thiocyanate Toxicity: Drug metabolism produces cyanide, detoxified by liver to thiocyanate, excreted in urine. Prolonged infusion (> several days) causes toxicity. Symptoms include fatigue, nausea, disorientation, acidosis, and muscular spasm. Monitor blood thiocyanate levels during prolonged use.
• Hypotension: Contraindicated in patients with preexisting hypotension. May cause profound hypotension and reflex tachycardia.
• Overdose Management: Drug withdrawal, recumbent position with leg elevation, IV fluid resuscitation, norepinephrine/vasopressin infusion (epinephrine contraindicated).

Nitrates (Nitroglycerin)

• Side Effects: Methemoglobinemia, tolerance, flushing, headache, hypotension, tachycardia.
• Contraindications: Increased intracranial pressure, hypovolemia.

Inodilators (Milrinone & Levosimendan)

• Milrinone: Hypotension secondary to peripheral vasodilation often necessitates IV fluid resuscitation. Renal clearance necessitates extreme caution in renal insufficiency. Associated with proarrhythmia, thrombocytopenia, transaminitis, and bronchospasm. Contraindicated in severe right/left ventricular outflow obstruction.
• Levosimendan: Symptomatic hypotension, palpitations, dizziness, nausea, vertigo.

Contraindicated Vasodilators in Pediatric HF

• Calcium Channel Blockers: Exert adverse negative inotropic effects; strictly avoided in pediatric heart failure unless specifically indicated for concurrent systemic hypertension.
• Hydralazine/Isosorbide Dinitrate (Bidil): Combination not recommended for pediatric patients due to high adverse reaction rates (headache, GI complaints) and lack of survival benefit superiority over ACE inhibitors in non-specific cohorts (Class III, LOE C).

Nuances in Specific Cardiac Phenotypes

Functionally Single Ventricle & Fontan Circulation

• Routine preventative ACE inhibition demonstrates no proven clinical benefit in patients lacking systolic dysfunction.
• Indicated strictly for afterload reduction in documented symptomatic heart failure to lower end-diastolic and pulmonary artery pressures.
• Phosphodiesterase inhibitors (milrinone) act favorably in early postoperative Fontan settings by providing afterload reduction without increasing pulmonary vascular resistance.

Restrictive Cardiomyopathy (RCM)

• Vasodilator therapy (ACEi/ARBs) carries significant risk.
• Hypotension frequently ensues without augmentation of cardiac output, due to strict inability to augment stroke volume against fixed diastolic restriction.
• Routine use of renin-angiotensin antagonists is not recommended for RCM unless alternative indications (e.g., hypertension) are present.

Right Ventricular Failure & Pulmonary Hypertension

• Decompensated right heart failure requires cautious optimization of RV preload.
• Excessive diuretic use or potent systemic vasodilation can drop cardiac output precipitously, compromising therapies aimed at lowering pulmonary vascular resistance.
• Inotropes (dobutamine/milrinone) utilized concurrently with IV diuretics improve CO. Systemic hypotension must be vigorously avoided (utilizing norepinephrine/vasopressin) to maintain RV coronary perfusion.